Background: This prespecified subgroup analysis of the FIDELIO-DKD trial aimed to evaluate the efficacy and safety of finerenone in patients with chronic kidney disease (CKD) and type 2 diabetes melli
Primary Objective: To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination (FRC) to insulin glargine in glycated hemoglobin (HbA1c) change from baseline to Week
Databases uploaded to this fileset under the terms and conditions of: - ClinicalTrials.govhttp://clinicaltrials.gov/ct2/about-site/terms-conditions - WHO ICTRP http://www.who.int/ictrp/search/download
